Sanguine Corp. Announces Agreement Which Signs Professor William Regelson, M.D., as Member of Sanguine Medical Advisory Board.Business Editors/Health & Medical Writers PASADENA, Calif.--(BUSINESS WIRE)--April 12, 2000 Agreement Also Announces Regelson as Assistant to Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. Admiral Van Orden Sanguine Corp. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: SGNC) Wednesday announced an agreement which signs Professor William Regelson, M.D., as a member of the Sanguine Medical Advisory Board and as an assistant to the Chief Operating Officer, Admiral Van Orden. Dr. Regelson is a professor of Medicine at the Virginia Commonwealth University Formed by a merger between the Richmond Professional Institute and the Medical College of Virginia in 1968, VCU has a medical school that is home to the nation's oldest organ transplant program. and has been a leading researcher in the field of aging and Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. for over 20 years. Regelson has written or edited several books and texts that are available on the mass market, focusing his research on the causes of the decline of the human body. Regelson's role is to identify PHER-O2 uses and implement research protocols and studies to prove PHER-O2's beneficial effects. Regelson is particularly suited to this position as he has researched and written on the discovery of amyloid plaques in the brain, which are thought to impede proper cerebral oxygenation oxygenation /ox·y·gen·a·tion/ (ok?si-je-na´shun) 1. the act or process of adding oxygen. 2. the result of having oxygen added. . Regelson's paper, published in the annals of the New York Academy of Sciences The New York Academy of Sciences is the third oldest scientific society in the United States. An independent, non-profit organization with more than 25,000 members in 140 countries, the Academy’s mission is to advance understanding of science and technology. in 1997, specifically hypothesizes the potential of PFCs, of which PHER-O2 is based, to oxygenate oxygenate /ox·y·gen·ate/ (-je-nat) to saturate with oxygen. ox·y·gen·ate or ox·y·gen·ize v. To treat, combine, or infuse with oxygen. plaque-encased regions of the brain may be used to alleviate the symptoms of Alzheimer's Disease. Regelson's numerous publications also include the following: Dehydroepiandrosterone, 1999; The Superhormone Promise: Nature's Antidote to Aging, 1997; The Melatonin melatonin: see pineal gland. melatonin Hormone secreted by the pineal gland of most vertebrates. It appears to be important in regulating sleeping cycles; more is produced at night, and test subjects injected with it become sleepy. Miracle: Nature's Age-Reversing, Disease-Fighting, Sex-Enhancing, 1995; Intervention in the Aging Process: Proceedings of the International Symposium on Intervention in the Aging Process, Boston, Nov. 5-6, 1982. Regelson, a medical oncologist by specialty, will benefit the Sanguine team through his expertise in the study of Alzheimer's Disease, as well as the proposed cancer fighting effects associated with the oxygen tension created by PHER-O2. Sanguine's PHER-O2 molecule contains 3-4 times the oxygen carrying capacity of human red blood corpuscles (Physiol.) in man, yellowish, biconcave, circular discs varying from Notice: This news release contains, and oral statements made from time to time by company representatives concerning the information contained herein may contain, so-called "forward-looking statements." These statements can be identified with introductory words such as "expects," "plans," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing the company's growth strategy, operating and financial goals, regulatory submissions and approvals and development programs. Many factors may cause actual results to differ from the company's forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion